Government Context

Documents Documents by topic Documents by agency Pricing Log in Create account

Login Create account

Nonrulemaking

Abbreviation New Drug Application (ANDA) suitablility for 7.5 mg of Cyclobenzaprine HCI-CLOSED

🏛 Food and Drug Administration (FDA)FDA-2003-P-0344

Documents

3

Total comments

0

all analyzed

Comment status

Closed

Last activity

—

In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

Other· Oct 19, 2004
Petition Approval from FDA CDER to Anabolic Laboratories, Inc.→
No comment period
Other· Oct 1, 2003
Acknowledgment Letter from FDA DMB to Anabolic Laboratoires, Inc.→
No comment period
Other· Oct 1, 2003
Acknowledgment Letter from FDA DMB to Anabolic Laboratoires, Inc.→
No comment period